13-32340330-C-T
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 0P and 1B. BP6
The NM_000059.4(BRCA2):c.5975C>T(p.Ser1992Leu) variant causes a missense change. The variant allele was found at a frequency of 0.00000372 in 1,613,860 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. S1992S) has been classified as Benign.
Frequency
Consequence
NM_000059.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -1 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BRCA2 | ENST00000380152.8 | c.5975C>T | p.Ser1992Leu | missense_variant | Exon 11 of 27 | 5 | NM_000059.4 | ENSP00000369497.3 | ||
BRCA2 | ENST00000530893.7 | c.5606C>T | p.Ser1869Leu | missense_variant | Exon 11 of 27 | 1 | ENSP00000499438.2 | |||
BRCA2 | ENST00000614259.2 | n.5975C>T | non_coding_transcript_exon_variant | Exon 10 of 26 | 2 | ENSP00000506251.1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152132Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.00000399 AC: 1AN: 250532Hom.: 0 AF XY: 0.00000737 AC XY: 1AN XY: 135696
GnomAD4 exome AF: 0.00000205 AC: 3AN: 1461728Hom.: 0 Cov.: 45 AF XY: 0.00000275 AC XY: 2AN XY: 727170
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152132Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74312
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:1Benign:2
Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673). -
The p.S1992L variant (also known as c.5975C>T), located in coding exon 10 of the BRCA2 gene, results from a C to T substitution at nucleotide position 5975. The serine at codon 1992 is replaced by leucine, an amino acid with dissimilar properties. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
- -
not specified Uncertain:2
Variant summary: BRCA2 c.5975C>T (p.Ser1992Leu) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 250532 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.5975C>T has been reported in the literature in individuals suspected of Hereditary Breast And Ovarian Cancer Syndrome undergoing BRCA1/2 testing (e.g. Caputo_2021, Bisgin_2022).One of these studies classified the variant as likely benign based on cosegregation analysis, however the detailed cosegregation data was not provided (Caputo_2021). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 35753294, 34597585). ClinVar contains an entry for this variant (Variation ID: 51979). Based on the evidence outlined above, the variant was classified as uncertain significance. -
This variant is denoted BRCA2 c.5975C>T at the cDNA level, p.Ser1992Leu (S1992L) at the protein level, and results in the change of a Serine to a Leucine (TCA>TTA). Using alternate nomenclature, this variant would be defined as BRCA2 6203C>T. This variant has not, to our knowledge, been published in the literature as pathogenic or benign. BRCA2 Ser1992Leu was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Serine and Leucine differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. BRCA2 Ser1992Leu occurs at a position that is not conserved and is located in the 7th BRC repeat and the RAD51 binding domain (Roy 2012). In silico analyses predict that this variant is probably damaging to protein structure and function. Based on currently available evidence, it is unclear whether BRCA2 Ser1992Leu is pathogenic or benign. We consider it to be a variant of uncertain significance. -
Breast-ovarian cancer, familial, susceptibility to, 2 Uncertain:1
- -
not provided Uncertain:1
BRCA2: PM2:Supporting, BP1 -
Hereditary breast ovarian cancer syndrome Benign:1
- -
BRCA2-related disorder Other:1
Variant interpreted as Uncertain significance and reported on 12-24-2019 by Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at